AOD-9604 Targeted Fat Burning Peptide Therapy in Hendersonville, Tennessee

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide derived from the C-terminal fragment of human growth hormone — specifically amino acids 177 to 191, the region of HGH responsible for its fat-metabolizing properties. By isolating this fragment, researchers created a highly targeted metabolic peptide that delivers the lipolytic (fat-burning) benefits of HGH without stimulating IGF-1 production or affecting insulin sensitivity.

AOD-9604 was originally developed by Monash University in Australia as an obesity treatment. Extensive clinical research has validated its safety and fat-burning efficacy, making it one of the most well-studied peptides in the metabolic therapy space.

How AOD-9604 Works

AOD-9604 targets fat tissue through two complementary mechanisms:

• Stimulates lipolysis — activates fat cells (adipocytes) to break down stored triglycerides and release fatty acids for energy
• Inhibits lipogenesis — suppresses the conversion of non-fat foods into stored fat, reducing new fat accumulation
• Targets stubborn areas — particularly effective on visceral fat (abdominal), subcutaneous fat, and other deposits resistant to diet alone
• Does not raise IGF-1 — no risk of the insulin resistance, joint pain, or cellular proliferation associated with full HGH therapy
• No blood sugar effects — unlike full HGH, AOD-9604 does not impair glucose metabolism

Who Benefits Most From AOD-9604?

AOD-9604 is particularly well-suited for patients who:

• Have stubborn fat deposits that don't respond to diet and exercise
• Want fat loss support without systemic hormonal effects
• Are seeking a complement to a GLP-1 therapy protocol
• Have concerns about IGF-1 elevation with traditional HGH therapy
• Are focused on body composition (fat loss while preserving muscle)
• Have metabolic syndrome or pre-diabetes with weight management challenges

AOD-9604 Protocols at Kanvas Wellness

At Kanvas Wellness in Hendersonville, TN, our specialist team designs AOD-9604 protocols tailored to each patient's metabolic profile and body composition goals. AOD-9604 is typically administered as a once-daily subcutaneous injection, most effectively taken in the morning on an empty stomach.

Many patients combine AOD-9604 with complementary peptides for comprehensive metabolic optimization:

• With Tesamorelin for enhanced body composition and visceral fat reduction
• With Ipamorelin or Sermorelin for broader growth hormone optimization
• As an adjunct to Semaglutide or Tirzepatide for comprehensive weight management

Expected Results

Most patients on AOD-9604 notice measurable changes in body composition within 4–8 weeks. Clinical trial data and clinical experience suggest:

• Reduction in stubborn fat deposits, particularly abdominal/visceral fat
• Improved muscle-to-fat ratio when combined with resistance training
• Enhanced fat burning during exercise
• Mild improvement in joint and cartilage health (AOD-9604 has shown cartilage-protective properties in research)